Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Arch Pediatr ; 25(8): 464-468, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30340941

RESUMEN

BACKGROUND: Infection is the major cause of treatment-related mortality in childhood acute leukemia, mainly due to bacterial translocation across the intestinal mucosa. Only a few studies have reported the impact of different antibacterial prophylaxis treatments on digestive tract flora and infection-related mortality. PROCEDURES: We performed a retrospective analysis of two different digestive tract decontamination modalities (selective or total digestive decontamination) in a large single-center series of 323 children during the induction treatment of acute leukemia between January 1995 and December 2014. We examined the impact of antibiotic prophylaxis and food regimen (sterile or selected) on the digestive tract flora during the period of antibacterial prophylaxis, on the frequency of bacteremia, and on antibiotic sensitivity. RESULTS: Only one Gram-negative (Klebsiella pneumonia) translocation occurred in the SDD group. No infection-related death occurred. Extended-spectrum beta-lactamase (ESBL) bacteria were observed in seven of 170 (4%) patients in the SDD group. The faecal-flora total suppression and faecal-flora Gram-negative bacilli suppression was 67 and 77%, respectively, in the TDD group with sterile food, 0 and 58%, respectively, in the SDD group with sterile food, and 6 and 63%, respectively, in the SDD group with selective food. CONCLUSIONS: This study gives a rationale not to use antibacterial prophylaxis systematically in children who receive induction treatment for acute leukemia; additionally, antibiotics should only be used in case of stool contamination by highly pathogenic bacteria with a high potential of translocation.


Asunto(s)
Antibacterianos/uso terapéutico , Profilaxis Antibiótica/métodos , Microbioma Gastrointestinal/efectos de los fármacos , Leucemia/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Antibacterianos/efectos adversos , Profilaxis Antibiótica/efectos adversos , Bacteriemia/microbiología , Niño , Preescolar , Descontaminación/métodos , Femenino , Humanos , Quimioterapia de Inducción , Lactante , Leucemia/complicaciones , Masculino , Estudios Retrospectivos
2.
Bone Marrow Transplant ; 50(11): 1438-44, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26191949

RESUMEN

We evaluated prospectively the incidence and risk factors of the metabolic syndrome (MS) and its components in 170 adult patients (mean age at evaluation: 24.8±5.4 years) who received an hematopoietic stem cell transplantation for childhood ALL, n=119, or AML, n=51. TBI was carried out in 124 cases; a busulfan-based conditioning was done in 30 patients. Twenty-nine patients developed a MS (17.1%, 95% confidence intervals: 11.7-23.6). The cumulative incidence was 13.4% at 25 years of age and 35.5% at 35 years of age. A higher body mass index (BMI) before transplantation and a growth hormone deficiency were associated with increased MS risk (P=0.002 and 0.01, respectively). MS risk was similar for patients who received TBI or busulfan-based conditioning. The TBI use increased the hyperglycemia risk (odds ratio (OR): 4.7, P=0.02). Women were at the risk of developing increased waist circumference (OR: 7.18, P=0.003) and low levels of high-density lipoprotein cholesterol (OR: 2.72, P=0.007). The steroid dose was not a risk factor. The MS occurs frequently among transplanted survivors of childhood leukemia. Its incidence increases with age. Both intrinsic (BMI, gender) and extrinsic factors (TBI, alkylating agents) contribute to its etiopathogenesis.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/efectos adversos , Síndrome Metabólico/etiología , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Sobrevivientes , Acondicionamiento Pretrasplante/efectos adversos , Corticoesteroides/administración & dosificación , Corticoesteroides/efectos adversos , Adulto , Antineoplásicos Alquilantes/efectos adversos , Antineoplásicos Alquilantes/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Glucemia/análisis , Índice de Masa Corporal , Busulfano/uso terapéutico , HDL-Colesterol/sangre , Terapia Combinada , Femenino , Humanos , Lípidos/sangre , Masculino , Síndrome Metabólico/sangre , Agonistas Mieloablativos/efectos adversos , Agonistas Mieloablativos/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Factores de Riesgo , Factores Sexuales , Circunferencia de la Cintura , Irradiación Corporal Total/efectos adversos , Adulto Joven
3.
Bone Marrow Transplant ; 49(5): 709-16, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24535128

RESUMEN

The purpose of this multicenter study was to compare the long-term impact of a preparative regimen with either BUBU or TBI on health status and quality of life (QoL) in childhood acute leukemia survivors treated with hematopoietic SCT (HSCT). Two-hundred and forty patients were included. Sixty-six had received BU, while 174 had received TBI. Median follow-up from HSCT was 10.1 years. Multivariate analyses were performed to assess the occurrence of late effects according to treatment. QoL was assessed in 130 adults using SF-36 questionnaires. Patients developed fewer late complications after BU (2.35 vs 3.01, P=0.03) while the risk to present with at least one complication was equivalent in both groups (87.9% after BU and 93.1% after TBI, P=0.66). Detailed multivariate analyses revealed a lower risk of height growth failure (OR=0.2), cataract (OR=0.1) and iron overload (OR=0.2) after BU, and an increased risk of overweight (OR=3.9) and alopecia (OR=11.2). SF-36 mental and physical composite scores were similar in both treatment groups and proved significantly lower than French norms. Late effects induced by BU might differ from those experienced after TBI. Although less frequent, they are still of considerable importance and may affect patients' QoL.


Asunto(s)
Busulfano/efectos adversos , Estado de Salud , Trasplante de Células Madre Hematopoyéticas , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Irradiación Corporal Total , Adolescente , Busulfano/administración & dosificación , Catarata/inducido químicamente , Niño , Preescolar , Femenino , Estudios de Seguimiento , Trastornos del Crecimiento/inducido químicamente , Humanos , Inmunosupresores/administración & dosificación , Inmunosupresores/efectos adversos , Lactante , Sobrecarga de Hierro/inducido químicamente , Masculino , Sobrepeso/inducido químicamente , Calidad de Vida , Sobrevivientes , Tiempo
4.
Bone Marrow Transplant ; 47(5): 684-93, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-21725370

RESUMEN

The literature contains a substantial amount of information about factors that adversely influence the linear growth in up to 85% of patients undergoing haematopoietic SCT (HSCT) with TBI and/or cranial irradiation (CI) for acute leukaemia (AL). By contrast, only a few studies have evaluated the impact of growth hormone (GH) therapy on growth rate and final height (FH) in these children. We evaluated growth rates during the pre- and post-transplant periods to FH in a group of 25 children treated with HSCT (n=22), TBI (n=21) or/and CI (n=8) for AL and receiving GH therapy. At the start of GH treatment, the median height Z-score was -2.19 (-3.95 to 0.02), significantly lower than at AL diagnosis (P<0.001). Overall height gain from start of GH treatment to FH was 0.59Z (-2.72 to 2.93) with a median height Z-score at FH of -1.35 (-5.35 to 0.27). This overall height gain effect was greater in girls than in boys (P=0.04). The number of children with heights in the reference population range was greater after than before GH therapy (P=0.07). At FH the GVHD and GH treatments lasting <2 years were associated with shorter FH (P=0.02 and 0.05). We found a measurable beneficial effect of GH treatment on growth up to FH.


Asunto(s)
Estatura/efectos de los fármacos , Estatura/efectos de la radiación , Irradiación Craneana/efectos adversos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Hormona de Crecimiento Humana/administración & dosificación , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Irradiación Corporal Total/efectos adversos , Niño , Preescolar , Femenino , Estudios de Seguimiento , Hormona de Crecimiento Humana/deficiencia , Humanos , Lactante , Masculino , Estudios Retrospectivos
5.
Bone Marrow Transplant ; 43(8): 637-42, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19011662

RESUMEN

We compared the impact of a conditioning regimen with BU (n=16) or fractionated TBI (n=42) on height growth during adolescence and final height (FH), in 58 adults transplanted for acute leukaemia before adolescence (younger than 9 for girls and 11 for boys, and prepubertal). Heights were measured at three key periods, that is, transplantation, before adolescence, and FH, and compared using height standard deviation score (SDS) and cumulative change in SDS. The influence of the conditioning regimen was assessed using multiple linear regression and adjusting for gender, central nervous system irradiation, age and leukaemia status at transplant and type of transplantation. Overall mean height SDS was near normal at transplantation and before adolescence (0.2+/-0.1 and -0.2+/-0.1, respectively), but decreased to -1.6+/-0.1 at FH. There were significant differences between the TBI and BU groups when comparing FH SDS (-1.8+/-0.2 vs -0.8+/-0.2, P=0.001), mean change in height SDS from transplantation to FH (-2+/-0.1 vs -1.1+/-0.2, P=0.002) and mean change in height SDS during adolescence (-1.6+/-0.1 vs -0.7+/-0.2, P=0.003). We conclude that preparations involving BU, although less toxic than TBI-containing regimens, also have adverse effects on growth, predominantly during adolescence.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Leucemia Mieloide Aguda/fisiopatología , Leucemia Mieloide Aguda/terapia , Leucemia-Linfoma Linfoblástico de Células Precursoras/fisiopatología , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Acondicionamiento Pretrasplante/métodos , Adolescente , Estatura , Niño , Femenino , Trastornos del Crecimiento/etiología , Humanos , Masculino , Inducción de Remisión , Factores de Tiempo , Resultado del Tratamiento , Irradiación Corporal Total
6.
Acta Anaesthesiol Belg ; 44(1): 17-23, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-8342400

RESUMEN

The aim of this study was to examine the value of systematic preoperative pulmonary function tests (PFTs) in order to reliably predict prolonged stay in I.C.U., prolonged mechanical ventilation and mortality in elective cardiac surgical patients. 149 consecutive adult patients (valvular replacement or coronary bypass graft) were studied retrospectively. We examined the preoperative respiratory data: vital capacity (VC), first second forced expired volume (FEV1), PaCO2 and PO2. Length of stay in I.C.U. (LICU), duration of mechanical ventilation (DMV), incidence of reintubation and survival rate were used as indices of respiratory morbidity. The results of the present study clearly indicate that patients with impaired airway flow rates had a prolonged postoperative recovery following cardiac surgery. Mortality, ICV and DMV increased when FEV1 was less than 1.5 L, VC was less than 2.5 L, or PaO2 was less than 8.5 kPa. Reintubation was associated with impaired flow rates. Pulmonary function tests appeared effective in predicting postoperative complications and the need for prolonged ventilatory support.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Cuidados Preoperatorios , Pruebas de Función Respiratoria , Procedimientos Quirúrgicos Cardíacos/mortalidad , Femenino , Volumen Espiratorio Forzado , Humanos , Unidades de Cuidados Intensivos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Oxígeno/sangre , Valor Predictivo de las Pruebas , Respiración Artificial , Estudios Retrospectivos , Tasa de Supervivencia , Capacidad Vital
8.
J Immunol Methods ; 9(1): 27-38, 1975 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-812918

RESUMEN

Polyacrylamide beads antibody immunoabsorbents were used in order to isolate human IgA, IgM and fragments of papain-digested human IgG. The proteins obtained were pure as judged by immunochemical techniques. The antisera raised with these purified proteins were monospecific. The binding capacity and the yield were satisfactory. These antibody immunoadsorbents offer several advantages; a) highly purified antigens can be quickly obtained in a one-step procedure from body fluids; b) their handling is easy especially when using a column; c) they can be used for a long period of time and for many experiments without any noticeable loss in their binding capacity.


Asunto(s)
Acrilamidas , Inmunoglobulina A/aislamiento & purificación , Fragmentos de Inmunoglobulinas/aislamiento & purificación , Inmunoglobulina G/análisis , Inmunoglobulina M/aislamiento & purificación , Absorción , Anticuerpos Antiidiotipos , Disgammaglobulinemia/inmunología , Humanos , Inmunoglobulina A Secretora/aislamiento & purificación , Cadenas alfa de Inmunoglobulina , Cadenas mu de Inmunoglobulina , Mieloma Múltiple/inmunología , Macroglobulinemia de Waldenström/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA